权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Serum pepsinogens of gastric cancer in Japan and China

日本和中国胃癌血清胃蛋白酶原

基本信息

批准号：
09045084
负责人：
MISUMI Junichi
金额：
$ 2.56万
依托单位：
Oita Medical University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B).
财政年份：
1997
资助国家：
日本
起止时间：
1997 至 1999
项目状态：
已结题

项目摘要

Medical examinations and investigations, which consisted of detailed interview on life-styles including eating habits, examination by a physician and measurement of blood pressure, urine test and blood examination were carried out in both Japan and China. Serum pepsinogens, gastrin, and anti-body titers to Helicobacter pylori were measured at the same time in Japan. Subjects in Japan were selected 4,073 people and 748 people from two different area of gastric cancer mortality in which SMR were 0.88 and 1.08 in male, but 0.96 and 0.96 in female. On the other hand, the populations in China from the three area with different gastric cancer mortality in Hebei province were studied as follows: In area H gastric cancer mortality (144.8/l00,000) we studied 438 people: area M, moderate mortality (105.7/l00,000) 510 people, and area L, low (36.3/100,000) 795 people. A total of 74 and 125 blood samples and pathological data of gastric cancer patients were collected from each corresponding areas in both Japan and China, respectively. Serum pepsinogens I, II and gastrin, and anti-body titers to H. pylori were measured to 859 subjects in Japan and 925 subjects in China selected from the above population who had almost same gastric cancer mortality rate 64.7/ 100,000 and 71.0/ 100,000, respectively.PG I and the ratio of PG I / II in Japan significantly decried compared with those in China. Couversely, PG II and gastrin in Japan significantly increased compared with those in China. On the other hand, although positivites to Helicobacter pylori in Japan and in China were different according to sex and age, they were 66.9% and 69.2% respectively. Analysis of biomarkers related to gastric cancer is now done routinely among gastric cancer patients in both Japan and China.

在日本和中国进行了医学检查和调查，包括详细的生活方式访谈，包括饮食习惯，医生检查和测量血压，尿检和血液检查。同时在日本测定血清胃蛋白酶原、胃泌素和幽门螺杆菌抗体滴度。研究对象来自日本两个不同的胃癌死亡地区，分别为4,073人和748人，男性SMR分别为0.88和1.08，女性SMR分别为0.96和0.96。另一方面，对河北省三个胃癌死亡率不同地区的人群进行了如下研究：H区胃癌死亡率（144.8/10万）438人，M区中度死亡率（105.7/10万）510人，L区低度死亡率（36.3/10万）795人。分别从日本和中国的相应地区收集了74份和125份胃癌患者的血液样本和病理资料。血清胃蛋白酶原I、II和胃泌素，以及抗H.从日本859例胃癌患者和中国925例胃癌患者中分别检测了PG I和PG I / II比值，结果显示，日本胃癌患者的PG I和PG I / II比值明显低于中国。与中国相比，日本的Couplatin、PG II和胃泌素显著升高。另一方面，虽然日本和中国的幽门螺杆菌阳性率因性别和年龄而异，但分别为66.9%和69.2%。在日本和中国，胃癌相关生物标志物的分析现在都是胃癌患者的常规分析。